Last updated: 4 September 2024 at 5:48pm EST

John Cox Net Worth




The estimated Net Worth of John Cox is at least $6.45 Million dollars as of 4 September 2024. John Cox owns over 32,000 units of Sigilon Therapeutics stock worth over $179,760 and over the last 14 years John sold SGTX stock worth over $6,269,659.

John Cox SGTX stock SEC Form 4 insiders trading

John has made over 26 trades of the Sigilon Therapeutics stock since 2011, according to the Form 4 filled with the SEC. Most recently John bought 32,000 units of SGTX stock worth $1,057,280 on 4 September 2024.

The largest trade John's ever made was exercising 36,234 units of Sigilon Therapeutics stock on 13 April 2011 worth over $2,055,555. On average, John trades about 3,910 units every 81 days since 2010. As of 4 September 2024 John still owns at least 8,000 units of Sigilon Therapeutics stock.

You can see the complete history of John Cox stock trades at the bottom of the page.



What's John Cox's mailing address?

John's mailing address filed with the SEC is C/O DYNE THERAPEUTICS, INC., 1560 TRAPELO ROAD, WALTHAM, MA, 02451.

Insiders trading at Sigilon Therapeutics

Over the last 4 years, insiders at Sigilon Therapeutics have traded over $2,000,000 worth of Sigilon Therapeutics stock and bought 2,018,493 units worth $31,039,916 . The most active insiders traders include Lilly & Co Eli, Lilly & Co Shenandoah Acqui..., and John Cox. On average, Sigilon Therapeutics executives and independent directors trade stock every 139 days with the average trade being worth of $7,174,671. The most recent stock trade was executed by Lilly & Co Shenandoah Acqui... on 11 August 2023, trading 1,718,493 units of SGTX stock currently worth $25,639,916.



What does Sigilon Therapeutics do?

Sigilon Therapeutics, Inc., a clinical stage biotechnology company, develops functional cures for patients with chronic diseases. Its lead product candidate is SIG-001, which is in Phase I/II clinical trial to prevent bleeding episodes in patients with moderate to severe Hemophilia A. The company is also developing SIG-005 to treat the non-neurological manifestations of mucopolysaccharidosis type 1; SIG-007 to provide continuous and prolonged release of functional enzyme at levels sufficient to produce clinical benefits and alleviate progression of the downstream aspects of Fabry disease; and SIG-002 to replace islet cells for the treatment of type 1 diabetes. Sigilon Therapeutics, Inc. has a research collaboration and license agreement with Eli Lilly and Company for the development and commercialization of SLTx product candidates for the treatment of Type 1 Diabetes. The company was formerly known as Sigilon, Inc. and changed its name to Sigilon Therapeutics, Inc. in June 2017. Sigilon Therapeutics, Inc. was incorporated in 2015 and is headquartered in Cambridge, Massachusetts.



What does Sigilon Therapeutics's logo look like?

Sigilon Therapeutics, Inc. logo

Complete history of John Cox stock trades at Biogen Inc, Repligen, Dyne Therapeutics, and Sigilon Therapeutics

Date
#
Company
Insider
Trans.
Transaction
Shares Price per share Total value Shares after Source
4 Sep 2024 John Cox
CEO and President
Buy 32,000 $33.04 $1,057,280
4 Sep 2024
8,000
24 Mar 2020 John Cox
Director
Sale 1,858 $96.72 $179,706
24 Mar 2020
923
18 Mar 2020 John Cox
Director
Option 26,736 $24.37 $651,556
18 Mar 2020
29,517
4 Mar 2020 John Cox
Director
Option 10,000 $12.91 $129,100
4 Mar 2020
12,781
24 Feb 2020 John Cox
Director
Sale 4,455 $92.81 $413,469
24 Feb 2020
2,781
23 Feb 2016 John Cox
EVP Pharmaceutical Oper and Tech
Option 810 $258.99 $209,782
23 Feb 2016
30,898
12 Feb 2016 John Cox
EVP Pharmaceutical Oper and Tech
Option 3,298 $247.22 $815,332
12 Feb 2016
31,145
8 Feb 2016 John Cox
EVP Pharmaceutical Oper and Tech
Option 4,026 $250.77 $1,009,600
8 Feb 2016
29,666
25 Mar 2015 John Cox
EVP Pharmaceutical Oper and Tech
Sale 12,010 $449.06 $5,393,211
25 Mar 2015
25,567
12 Feb 2015 John Cox
EVP Pharmaceutical Oper and Tech
Option 3,738 $392.11 $1,465,707
12 Feb 2015
33,214
8 Feb 2015 John Cox
EVP Pharmaceutical Oper and Tech
Option 8,714 $402.00 $3,503,028
8 Feb 2015
32,744
23 Feb 2014 John Cox
EVP Pharmaceutical Oper and Tech
Option 2,598 $347.11 $901,792
23 Feb 2014
26,706
12 Feb 2014 John Cox
EVP Pharmaceutical Oper and Tech
Option 2,246 $323.04 $725,548
12 Feb 2014
25,167
8 Feb 2014 John Cox
EVP Pharmaceutical Oper and Tech
Option 8,714 $315.54 $2,749,616
8 Feb 2014
25,133
23 Feb 2013 John Cox
EVP Pharmaceutical Oper and Tech
Option 2,598 $164.40 $427,111
23 Feb 2013
19,986
8 Feb 2013 John Cox
EVP Pharmaceutical Oper and Tech
Option 8,179 $164.44 $1,344,955
8 Feb 2013
19,224
23 Feb 2012 John Cox
EVP Pharmaceutical Oper and Tech
Option 2,600 $116.70 $303,420
23 Feb 2012
15,376
9 Feb 2012 John Cox
EVP Pharmaceutical Oper and Tech
Option 4,692 $117.78 $552,624
9 Feb 2012
14,280
1 Nov 2011 John Cox
EVP Pharmaceutical Oper and Tech
Option 2,175 $72.87 $158,492
1 Nov 2011
11,763
21 Apr 2011 John Cox
EVP Pharmaceutical Oper and Tech
Option 4,350 $72.87 $316,985
21 Apr 2011
14,703
13 Apr 2011 John Cox
EVP Pharmaceutical Oper and Tech
Option 36,234 $56.73 $2,055,555
13 Apr 2011
46,587
11 Apr 2011 John Cox
EVP Pharmaceutical Oper and Tech
Option 6,900 $47.92 $330,648
11 Apr 2011
17,253
31 Mar 2011 John Cox
EVP Pharmaceutical Oper and Tech
Option 2,840 $43.50 $123,540
31 Mar 2011
12,658
2 Mar 2011 John Cox
EVP Pharmaceutical Oper and Tech
Sale 4,041 $70.10 $283,274
2 Mar 2011
9,818


Sigilon Therapeutics executives and stock owners

Sigilon Therapeutics executives and other stock owners filed with the SEC include: